17415923. DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES simplified abstract (Novartis AG)

DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES

Organization Name

Novartis AG

Inventor(s)

Simone Bonazzi of Cambridge MA (US)

Adam Crystal of Newton MA (US)

John Scott Cameron of Cambridge MA (US)

Eva Marie Genevieve D'hennezel of Cambridge MA (US)

Glenn Dranoff of Cambridge MA (US)

Ry Roger Forseth of West Orange NJ (US)

Dominik Johannes Hainzl of Cambridge MA (US)

Jacqueline Kinyamu-akunda of East Hanover NJ (US)

Guiqing Liang of Cambridge MA (US)

Lilly Mary Petruzzelli of Cambridge MA (US)

DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES - A simplified explanation of the abstract

This abstract first appeared for US patent application 17415923 titled 'DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES

The present disclosure pertains to dosing regimens, formulations, and combinations containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds or pharmaceutical compositions with the same; and methods of using such combinations and compositions in the treatment or prevention of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases or disorders or where reduction of IKZF2 or IKZF4 protein levels can ameliorate a disease, such as the treatment of cancers.

• Novel dosing regimens, formulations, and combinations involving 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds are disclosed.
• The patent covers pharmaceutical compositions containing the mentioned compounds for treating IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases or disorders.
• Methods for utilizing the disclosed combinations and compositions in the treatment or prevention of diseases where reducing IKZF2 or IKZF4 protein levels can be beneficial are outlined.
• The technology focuses on the potential therapeutic applications of targeting IKAROS Family Zinc Finger 2 (IKZF2) in various diseases, particularly cancers.
• The patent addresses the need for more effective treatments for IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases and disorders, offering a new approach to managing these conditions.

Potential Applications

The technology has potential applications in the development of targeted therapies for IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases, including certain types of cancers.

Problems Solved

This technology addresses the challenge of effectively targeting IKAROS Family Zinc Finger 2 (IKZF2) in diseases where its overexpression or dysregulation plays a significant role in pathogenesis.

Benefits

The benefits of this technology include the potential for more precise and effective treatments for IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases, potentially leading to improved patient outcomes and quality of life.

Commercial Applications

Title: Targeted Therapies for IKAROS Family Zinc Finger 2 (IKZF2)-Dependent Diseases This technology could have significant commercial applications in the pharmaceutical industry, particularly in the development of novel therapies for cancers and other diseases driven by IKAROS Family Zinc Finger 2 (IKZF2) dysregulation.

Questions about the Technology

1. What are the specific mechanisms by which reducing IKZF2 or IKZF4 protein levels can ameliorate diseases? 2. How do dosing regimens and formulations containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds differ from existing treatments for IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases?

Original Abstract Submitted

The present disclosure relates to dosing regimens, formulations, and combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds or pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases or disorders or where reduction of IKZF2 or IKZF4 protein levels can ameliorate a disease, for example, the treatment of cancers.